EveryLife Foundation for Rare Diseases Comments on FDA-2017-N-3615: Administering The Hatch-Waxman Amendments

November 17, 2017

Share this page

Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments; Extension of Comment Period

Related Articles

The EveryLife Foundation Submits Comments to Support Patient-Focused Drug Development and Medical Innovation July 01, 2026
EveryLife Foundation submits written comment to the FDA on the Reauthorization of Medical Device User Fee Agreements (MDUFA) October 20, 2025
EveryLife Submits Comments Supporting Prioritization of FDA Rare Disease Innovation Hub November 01, 2024